Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma

Abstract

P Z 0.0016). Within the 100 genes, enriched biological functions relate to clusters of genes governing protein degradation, RNA processing, apoptosis, the cell cycle, ATP synthesis, and a large cluster of genes relating to protein localization. Conclusion: We have identified three novel intrinsic subtypes of prostate cancer in the largest study of its kind, and validated our findings across sequencing platforms, storage methods, and within both retrospective and prospective cohorts. In defining unique biological clusters of disease, the PC100 represents a step towards personalization of prostate cancer care. Future work will focus on validating the predictive capacity of these subtypes to therapy such as radiation therapy.

Outcomes and toxicities in patients with intermediate‐risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy

“…Follow‐up was short and an older definition of PSA failure (ASTRO) was used. The RTOG study also found that EBRT slightly increased toxicity in patients with one intermediate‐risk factor . Findings are consistent with previous studies that found that dose but not the addition of EBRT predicted FfBF .…”

“…The American Brachytherapy Society consensus guidelines recommend monotherapy brachytherapy in low‐risk patients but regimens for intermediate‐risk patients are less well defined . Recently, the Radiation Therapy Oncology Group (RTOG) conducted a randomized study of patients with prostate cancer with one intermediate‐risk factor treated with implant only or implant and EBRT . Their results indicated equivalence in freedom from biochemical failure (FfBF), overall survival, distant metastasis rate, and prostate cancer‐specific mortality.…”

Prostate Cancer

“…Brachytherapy, which is highly conformal therapy, appears to have lower SPC risk than EBRT. 607 The results of this study are expected to clarify the role of EBRT in men receiving permanent seed brachytherapy. In the early 1990s, palladium-103 ( 103 Pd) was introduced.…”

Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning

“…These include the randomized clinical trials performed at the Schiffler Cancer Institute (n=630), 35,36 and the RTOG 0232 study (n=588). 37 Each demonstrated that sEBRT did not improve progression-free or overall survival (REF: ASTRO 2016 PLENARY – Need IJROBP supplemental ref – CURRENTLY EMBARGOED).…”